Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00037570 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
A Phase 2 study of Peptic Ulcer Hemorrhage, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 6
- Study locations
NCT00037570 is a Phase 2 study of Peptic Ulcer Hemorrhage that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 12 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT00037570, a Phase 2 study of Peptic Ulcer Hemorrhage, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients. Patients will receive either intravenous pantoprazole (one of two regimens) or ranitidine (the comparator) within 2 hours of successful hemostasis and administration will continue for 72 hours after hemostasis.
Conditions Studied
Interventions
- DRUG Pantoprazole
Study Locations (6)
California
- - Los Angeles
- - San Diego
Ohio
- - Cincinnati
Pennsylvania
- - Philadelphia
Texas
- - Houston
Virginia
- - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2000-11 |
| Est. Completion | 2002-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00037570
The ClinicalTrials.gov registry entry for NCT00037570 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peptic Ulcer Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Pantoprazole is the first listed.
NCT00037570 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00037570 about?
NCT00037570 is a clinical study titled "Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage". This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients. Patients will receive either intravenous pantoprazole (one of two regimens) or ...
What is the current status of trial NCT00037570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2000-11. Estimated completion is 2002-02.
What conditions does trial NCT00037570 study?
This clinical trial studies the following conditions: Peptic Ulcer Hemorrhage.
What interventions are being tested in trial NCT00037570?
The interventions under investigation include: Pantoprazole (DRUG).
Who is sponsoring clinical trial NCT00037570?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00037570 being conducted?
This trial has 6 study locations across California, Ohio, Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peptic Ulcer Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.